View Online

Immunotherapeutic strategies for canine lymphoma:

What place for the autologous therapeutic vaccine APAVAC®?

  


 

Relevant canine lymphoma model

Due to its many similarities with human non-Hodgkin's lymphoma (intact immune system, genetic interactions, equivalent environmental exposures, diagnostic protocols), canine lymphoma is increasingly being considered as a model for comparative medicine in immuno-oncology (1).


Panel of Veterany immunotherapeutic stratégies under development

All the major immunotherapy families are being explored in the treatment of canine lymphoma (2):

- Monoclonal antibodies promote direct or indirect cancer cell death,

- Adoptive cell transfer uses the patient's own cells to induce antitumor activity,

- Oncolytic virotherapy uses a replication-competent virus to eliminate cancer,

- Immunomodulators aim to boost immune responses and tumor control,

- Vaccines stimulate the patient's immune system against cancer cells.

 

However, for a variety of economic and/or regulatory reasons, not all of them have access to the veterinary market.


APAVAC® autologous vaccination available:




Hastim® provides to the veterinarians a kit  with all components which permit to do an extemporaneous preparation, based on a sample of around 1 cm3 of tumor biopsy (500 mg).

The principle consists in selecting, concentrating and fixing tumor antigens, combined with heat shock proteins, on a hydroxyapatite support, which is then injected into the animal according to a precise vaccination schedule.

This personalized, pain-free immunotherapy, which respects the animal's body with no side effects, is considered a standard in the treatment of canine diffuse large-cell B lymphoma, in association with low therapeutic index chemotherapy(3-5).




​

The 4 strengths of APAVAC® specific immunotherapy


    1.    Proven clinical efficacy

    2.    Personalized and adapted to the progression of the disease

    3.    Accessible and easy to implement

    4.    Non-toxic for the animal and its environment

 

 

More Information  ?

-       Want to discuss using APAVAC® on an animal in your care?

-       Would you like to order?

​ ​ ​ ​Visit our website www.hastim.fr

​ ​ ​​​Contact us by e-mail: adv@hastim.fr or by telephone: 00 33 5 34 47 86 10


 1. Villarnovo D, et coll.: Barking up the right tree: advancing our understanding and treatment of lymphoma with a spontaneous canine model. Curr Opin Hematol. 2017
2. Dias JNR, et coll.: Immunotherapeutic Strategies for Canine Lymphoma: Changing the Odds Against Non-Hodgkin Lymphoma. Front Vet Sci. 2021
3. Marconato L et coll.: Randomized, placebo-controlled, double-blinded chemoimmunotherapy clinical trial in a pet dog model of diffuse large B-cell lymphoma. Clin Cancer Res. 2014
4. Marconato L et coll.: Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers. J Immunother Cancer 2019
5. Marconato L, et coll.:. Enhanced therapeutic effect of APAVAC immunotherapy in combination with dose-intense chemotherapy in dogs with advanced indolent B-cell lymphoma. Vaccine 2015

Se désabonner